Cevostamab Validates FcRH5 in Late-Line Myeloma
A full peer-reviewed analysis of Roche and Genentech’s cevostamab phase 1 program establishes FcRH5 as a clinically active multiple-myeloma target. At the 160 mg recommended phase 2 dose, fixed-duration cevostamab produced a 44.3% objective…
